Monday, 02 October 2023



LATEST NEWS Massive cleanliness drives conducted at 4000 places in Ganderbal Swachhata Pakhwada cleanliness drives held across Kulgam DLSA Kupwara holds cleanliness drive at District Court Complex Information Deptt, Shopian organizes cleanliness drives, Swatchta Shapath Extensive cleanliness Drive under "Swachhta Hi Seva Campaign" held in Kupwara JDI Mohammad Aslam awarded Certificate of Appreciation for contribution in Shramadaan Swachh Bharat PCCF Roshan Jaggi reviews working of Forest Deptt in Awantipora, Lidder Divisions Swachhata Hi Seva : High Court organize cleanliness drive Legal Services Institutions observe Swachhata Pakhwada - “Swachhata Hi Sewa” across J&K Technology has immense potential to bring government and citizens’ closer”: V Srinivas Sanitation cum Awareness Campaign Launched across Baramulla Distt “Swachta hi Seva”: Forest Department organizes series of activities; UT level event held at Shankaracharya Srinagar ‘Swachhata hi Seva’ : Comm Secy RDD Mandeep Kaur inaugurates Mega cleanliness drive at Chatlam Wetland Reserve Pulwama ‘Swachhata Hi Seva’ : Secretary H&ME Bhupinder Kumar launches campaign at LD Hospital, Srinagar “Swachhata Hi Seva” : ACS Home launches cleanliness, plantation drive at Central Jail Srinagar J&K Pollution Control Committee conducts "Swachhata Hi Seva" cleanliness drive Mega cleanliness drive organized by Amar Singh college Horticulture, Kashmir celebrated ‘Swachhata Hi Seva’ JKEDI organizes cleanliness drives across UT On the clarion call of hon'ble Prime Minister, Shramdaan held at the War Memorial, Amritsar DLSA Shopian conducts Sanitation Drive at Shopian


2-DG effective against all Covid variants, says study

 Health, Study, Coronavirus, COVID 19, Novel Coronavirus, Covaxin, Covishield, Covid-19 Vaccine, Covid-19 Vaccine in London, COVID-19 Vaccination, COVID Vaccination, Coronavirus Vaccine
Listen to this article

Web Admin

Web Admin

5 Dariya News

Hyderabad , 15 Jun 2021

The 2-deoxy-D-glucose (2-DG) developed by the Defence Research and Development organisation (DRDO) for the coronavirus treatment, effectively inhibits the SARS-CoV-2 multiplication and works against all variants of Covid-19, says a research study. In conclusion, our findings suggest that 2-DG effectively inhibits the SARS-CoV-2 multiplication and can be used as a treatment regimen. Glycolytic inhibitor 2-DG attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions (virus), concludes the study by researchers from Centre for Cellular and Molecular Biology (CCMB), Hyderabad, Institute of Nuclear Medicine and Allied Sciences, Delhi, and Academy for Scientific and Innovative Research, Ghaziabad. "Although the effect of 2-DG has been analyzed on only 2 different SARS-CoV-2 variants (B.6 and B.1.1.7), its anti-viral property is suggested to be universal on all the variants of SARS-CoV-2, as 2-DG interferes with the metabolic requirement of virus infected host cells," says the research study published in the preprint online server 'BioRxiv' The findings highlight the SARS-CoV-2 infection mediated enhanced glucose metabolism in host cells, which can be targeted for therapeutic application. "2- DG exploits the inherent and natural mechanism of infected host cells for selective, high accumulation of the drug without compromising uninfected/ normal cell functioning. 2-DG by inhibiting both catabolic and anabolic pathways reduces the virus replication and reduces the infectivity of the progeny virions, which has a compromised potential of infection in neighbouring cells." Anant Narayan Bhatt, Abhishek Kumar, Yogesh Rai, Neeraj Kumari, Dhiviya Vedagiri, Krishnan H. Harshan, C. Vijaya Kumar and Sudhir Chandna are the researchers involved in the study, the first on 2-DG "We demonstrate that glycolytic inhibitor 2-DG exhibits significant potential to be developed as a therapeutic to combat the Covid. These experimental evidences and previous clinical trial experience of 2-DG made way for this molecule to reach clinical trials in Covid patients in India," says the study. "Our results showed that virus infection induces glucose influx and glycolysis resulting in selective high accumulation of the fluorescent glucose/2-DG analogue, 2-NBDG in these cells. Subsequently, 2-DG reduces the virus multiplication and alleviates the cells from infection induced cytopathic effect (CPE) and cell death. Herein, we demonstrate that progeny virions produced from 2-DG treated cells are defective with compromised infectivity potential." "Further, it was also observed that mannose inhibits 2-NBDG uptake at a very low concentration, suggesting that 2-DG uptake in virus-infected cells might be exploiting the specific mannose transporter or high-affinity glucose transporter, GLUT3, which was found to be increased on SARS-CoV-2 infection," it added. The drug developed by DRDO in collaboration with Hyderabad-based Dr Reddy's Laboratories was approved by the Drugs Controller General of India (DGCI) last month for emergency use as an adjunct therapy in moderate to severe coronavirus patients. The drug is available in powder form in a sachet, and can be taken orally after dissolving in water. It has been priced Rs 990 per sachet. According to the government, the clinical trial data shows that the molecule helps in faster recovery of patients hospitalised with Covid-19, and reduces their dependence on supplemental oxygen.


Tags: Health , Study , Coronavirus , COVID 19 , Novel Coronavirus , Covaxin , Covishield , Covid-19 Vaccine , Covid-19 Vaccine in London , COVID-19 Vaccination , COVID Vaccination , Coronavirus Vaccine



related news




Photo Gallery



Video Gallery



5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2023 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD